The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized phase III trial comparing pegylated liposomal doxorubicin (PLD) 50 mg/m2 and 40 mg/m2 in patients with platinum-resistant Müllerian carcinoma (JGOG3018).
 
Akira Yabuno
No Relationships to Disclose
 
Tsutomu Tabata
Honoraria - AstraZeneca; Chugai Pharma
 
Hirofumi Michimae
No Relationships to Disclose
 
Tetsuro Oishi
No Relationships to Disclose
 
Miwa Nonaka
No Relationships to Disclose
 
Masashi Takano
No Relationships to Disclose
 
Toru Hirata
No Relationships to Disclose
 
Keiichi Fujiwara
Honoraria - Bayer; Chugai Pharma; Daiichi Sankyo; Eisai; Janssen Oncology; Kyowa Hakko Kirin; Lilly Japan; Nippon Kayaku; Ono Pharmaceutical; Taiho Pharmaceutical; Zeria Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Eisai; MSD; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Kaken Pharmaceutical (Inst); Lilly (Inst); MSD (Inst); Oncotherapeutics (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Zeria Pharmaceutical (Inst)
 
Toru Sugiyama
No Relationships to Disclose